Research Article
Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity
Table 1
Changes in laboratory values.
| | | Baseline | End of follow-up | value |
| | Creatinine, median (IQR), µmol/L | 84.9 (73.8; 97.5) | 78 (69.9; 91) | 0.013 | | Abnormal creatinine values, n (%) | 10 (16.9) | 3 (5.1%) | 0.125 | | eGFR (CKD EPI), median, (IQR), mL/min/1.73 m2 | 87.7 (67; 99) | 89.9 (73.6; 99.3) | 0.017 | | eGFR (CKP EPI), n (%) <60 mL/min/1.73 m2 | 9 (15.3%) | 1 (1.7%) | 0.031 | | eGFR (CKP EPI), n (%) ≥90 mL/min/1.73 m2 | 25 (42.4%) | 23 (39%) | 0.549 | | Serum phosphate levels, mmol/L, median (IQR) | 1.02 (0.9; 1.13) | 1.00 (0.9.; 1.5) | 0.632 | | Abnormal phosphate levels, n (%) | 12 (23%) | 9 (21%) | 0.319 | | Urine albumin/creatinine ratio (mg/g) | 18.4 (3; 56) | 8.7 (1.7; 38) | 0.446 | | Abnormal urine albumin/creatinine ratio, n (%) | 11 (18.6%) | 8 (13.6%) | 1 | | Urine protein/creatinine ratio (mg/g) | 180.5 (95; 322) | 85 (69; 198) | 0.118 | | Abnormal urine protein/creatinine ratio, n (%) | 22 (37%) | 8 (13.6%) | 0.057 | | Urine hemoglobin | 19 (32.2%) | 11 (18.6%) | 0.068 | | Glycosuria, n (%) | 4 (6.8%) | 0 | 0.18 |
|
|
TDF: tenofovir disoproxil fumarate; IQR: interquartile range; eGFR: estimated glomerular filtration rate; CKD EPI: Chronic Kidney Disease Epidemiology Collaboration; : number of patients.
|
